NanoViricides Stock Forecast, Price & News

-0.15 (-3.40 %)
(As of 06/14/2021 11:36 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,032 shs
Average Volume1.48 million shs
Market Capitalization$49.01 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter.

About NanoViricides

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.42 out of 5 stars

Medical Sector

1776th out of 2,099 stocks

Pharmaceutical Preparations Industry

747th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions

What stocks does MarketBeat like better than NanoViricides?

Wall Street analysts have given NanoViricides a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NanoViricides wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NanoViricides' next earnings date?

NanoViricides is scheduled to release its next quarterly earnings announcement on Tuesday, October 12th 2021.
View our earnings forecast for NanoViricides

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSEAMERICAN:NNVC) issued its quarterly earnings results on Friday, May, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.
View NanoViricides' earnings history

When did NanoViricides' stock split? How did NanoViricides' stock split work?

NanoViricides's stock reverse split on the morning of Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Dr. Anil R. Diwan, Exec. Chairman, Pres, CEO & Sec. (Age 62, Pay $400k)
  • Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA, Chief Financial Officer (Age 62, Pay $129.6k)
  • Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 74)

Who are some of NanoViricides' key competitors?

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA).

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

Who are NanoViricides' major shareholders?

NanoViricides' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.61%), Compagnie Lombard Odier SCmA (0.37%), Blueshift Asset Management LLC (0.19%), First Financial Bank Trust Division (0.10%) and Commonwealth Equity Services LLC (0.10%).
View institutional ownership trends for NanoViricides

Which major investors are buying NanoViricides stock?

NNVC stock was bought by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Geode Capital Management LLC, Blueshift Asset Management LLC, First Financial Bank Trust Division, and Commonwealth Equity Services LLC.
View insider buying and selling activity for NanoViricides
or or view top insider-buying stocks.

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $4.26.

How much money does NanoViricides make?

NanoViricides has a market capitalization of $49.01 million.

How many employees does NanoViricides have?

NanoViricides employs 17 workers across the globe.

What is NanoViricides' official website?

The official website for NanoViricides is www.nanoviricides.com.

Where are NanoViricides' headquarters?

NanoViricides is headquartered at 1 Controls Dr, SHELTON, CT 06484-6153, United States.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.